Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results

June 14, 2021 6:00 PM

RICHMOND HILL, ON / ACCESSWIRE / June 14, 2021 / Helix BioPharma Corp. (TSX:HBP), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2021.OVERVIEWThe Company reported a net loss and total comprehensive loss of $2,554,000 and $5,268,000 for the three and nine-month periods ended April 30, 2021. For the three and...

Read more

BillionToOne Closes $55M Series B Funding, Builds Out a 36,000 Sqft Space to Meet Growing Demand

June 14, 2021 12:00 PM

MENLO PARK, CA / ACCESSWIRE / June 14, 2021 / Today, BillionToOne, Inc., the precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all, announced the closure of a heavily oversubscribed Series B funding round of $55 million with premier global investors. Existing investor Hummingbird Ventures and incoming investor Four Rivers Group led the investment round alongside significant...

Read more

EV Biologics is now Pink Current

June 14, 2021 9:00 AM

CHEYENNE, WY / ACCESSWIRE / June 14, 2021 / EV Biologics Corp (OTC PINK:YECO) today announced that it has completed all its filings on OTC Markets and is now Pink Current.Being current and Penny Stock Exempt allows the majority of brokers to trade in our stock.CEO Daniel Mckinney, said 'we are pleased to be current in our filings and are now focused on developing innovative regenerative biologics including engineered exosomes and other stem...

Read more

MERIT Study Investigators Announce Successful Achievement of the Study's Primary Efficacy & Safety Endpoints

June 14, 2021 7:30 AM

AUSTIN, TX / ACCESSWIRE / June 14, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that investigators of the Multi-Center ESG Randomized Interventional (MERIT) study have reported based on a preliminary analysis the successful achievement of the study's primary endpoints.In a presentation at the 2021 Surgical Disruptive...

Read more

Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe

June 14, 2021 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / June 14, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutic to clinical trials and distribution throughout Europe. Completion of these steps will establish its anti-HIV therapy as a significant revenue source for the Company, a meaningful milestone for both human health and Company profitability.The...

Read more

Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep

June 13, 2021 4:00 PM

Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in both hospitalized and ambulatory settingsZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 13, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin®...

Read more

Viewpoint Molecular Targetin(TM) Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma

June 10, 2021 10:00 AM

- VMT01 Phase 1 imaging study followed by Phase 1/2a therapy study for the treatment of metastatic melanoma being conducted at Mayo Clinic -- Positive preclinical data have demonstrated that a single dose of [212Pb]-VMT01 has significantly arrested melanoma tumor growth and extended survival -- VMT01 imaging study provisional results expected in Q4 2021 -CORALVILLE, IA / ACCESSWIRE / June 10, 2021 / Viewpoint Molecular Targeting, Inc....

Read more

Green Planet Group Secures Long-Term Funding

June 9, 2021 9:00 AM

PHOENIX, AZ / ACCESSWIRE / June 9, 2021 / Green Planet Group, Inc. (OTC PINK:GNPG), an emerging leader in green technology, announced today that it has secured funding that will provide it with the capital required to continue its growth into a profitable company. The investors have already met their initial funding commitments and have pledged additional capital, as needed in the future. According to the investors, "Rarely does an industry...

Read more

Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform

June 9, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') is releasing a White Paper outlining 5 innovative ways to improve patient engagement in clinical trials. The five key points in the White Paper (which can be found here: https://www.oncology-pharma.com/white-papers are: Health Literacy, Patient Concierge Service, Trial Support Community, Easy-to-use User Interface, and...

Read more

Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States

June 9, 2021 7:45 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 9, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') pursuant to a registration statement on Form F-1 (File No. 333-255447), as amended, that has been...

Read more

Pressure BioSciences to Present at the LD Micro Virtual Invitational Conference XI

June 8, 2021 10:15 AM

Company Invites Individual and Institutional Investors, as well as Advisors and Analysts, to Attend the Company's Virtual Presentation on Thursday, June 10, 2021SOUTH EASTON, MA / ACCESSWIRE / June 8, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life sciences, agriculture, food...

Read more

Edesa Biotech to Attend BIO Digital 2021

June 8, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company's senior management are scheduled to attend the 2021 BIO Digital Conference being held June 14-18, 2021.Members of the biopharma or investment community who are interested in meeting with Edesa during the conference may contact the company on...

Read more

Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

June 8, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the beginning of enrollment of the second cohort in dosing patients for its Phase I trial for Brain Cancer. This milestone allows the trial to...

Read more

heliosDX and RushNet Inc. Sign Binding Letter of Intent to Acquire Laboratory and Target Additional Laboratory Acquisitions

June 7, 2021 8:00 AM

ALPHARETTA, GA / ACCESSWIRE / June 7, 2021 / RushNet, Inc (OTC PINK:RSHN) ("RushNet") with merger/acquisition target heliosDX, is pleased to announce a Binding Letter of Intent by heliosdDX to acquire a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests.The acquisition further increases the National footprint of heliosDX while also reducing costs,...

Read more

BioLargo (BLGO) to Present at LD Micro Invitational XI

June 4, 2021 8:30 AM

Presentation on Wednesday, June 9 at 5:00 PM ET WESTMINSTER, CA / ACCESSWIRE / June 4, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it will be giving an investor presentation at the upcoming LD Micro virtual event on Wednesday, June 9, 2021, at 5:00 PM ET. BioLargo President and CEO Dennis P. Calvert will be giving the...

Read more

CEO Of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug Development Summit

June 3, 2021 10:15 AM

TUCSON, AZ / ACCESSWIRE / June 3, 2021 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute and chronic diseases, will be participating in the first annual Acute Respiratory Distress Syndrome (ARDS) Drug Development Summit from July 13th-15th. This virtual summit includes several of the world's top experts on...

Read more

Applied UV Sign Exclusive Distribution Agreement with Vietnam Distributor for Airocide(R) Air Purification Systems

June 3, 2021 8:30 AM

Distributor will provide fast access to a high growth market MOUNT VERNON, NY / ACCESSWIRE / June 3, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically,...

Read more

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

June 3, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's drug candidate EB01 has met a key interim study parameter. The company has now passed the initial inflection point of its Phase2b study and will continue enrolling the final cohort of patients. Edesa reported that interim study data...

Read more

Lesotho Government Supports M2Bio Sciences Blockchain Initiatives

June 2, 2021 9:35 AM

CAPE TOWN, SA / ACCESSWIRE / June 2, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: The Lesotho Government has lent its official support to two blockchain initiatives being implemented by M2Bio Sciences. This was confirmed in a letter written to M2Bio...

Read more

Applied UV's Airocide(R) System Installed in Judges Rooms to Protect Participants at the 28th Grand International Wine Award "MUNDUS VINI" 2021

June 2, 2021 8:30 AM

Installation of Fifty Airocide® Systems Highlights Growing Demand for Better Air Quality at Live Indoor Events Leveraging industry recognition to expand market share in rapidly growing wine industry Airocide® Named Official Partner of "MUNDUS VINI" 2021 MOUNT VERNON, NY / ACCESSWIRE / June 2, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology...

Read more